MedTrace Logo

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma

NCT01037478 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.

Conditions

  • Hodgkin's Lymphoma

Interventions

DRUG

Resminostat (4SC-201)

oral administration

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Jan Walewski, Prof. · Instytut im. Marii Skłodowskiej-Curie, Centrum Onkologii, Warsaw, Poland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-01-31
Completion
2013-03-31

Countries

  • Czechia
  • Poland
  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037478 on ClinicalTrials.gov